Trials / Completed
CompletedNCT01188603
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Evaluation of Single Dose and Steady State Pharmacokinetics of Flibanserin Postmenopausal Women With Hypoactive Sexual Desire Disorder
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Sprout Pharmaceuticals, Inc · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | flibanserin 100 mg dose every evening | all subjects receive flibanserin |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2010-08-25
- Last updated
- 2014-05-21
- Results posted
- 2012-04-10
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01188603. Inclusion in this directory is not an endorsement.